GlassScriptPhysician profile
Steven H Fehrenkamp
NPI 1376582718
$6,719.85
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $1,970 · 2021: $2,000 · 2022: $766.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,065.71 | 2019-2022 | |
| Lilly USA, LLC | $934.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $852.42 | 2019-2022 | |
| Ibsa Pharma INC. | $662.47 | 2019-2021 | |
| Abbvie INC. | $493.65 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $400.43 | 2019-2022 | |
| Amarin Pharma, INC. | $289.26 | 2019-2021 | |
| Amgen INC. | $241.33 | 2019-2021 | |
| Mannkind Corporation | $197.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.94 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.63 | 2022 | |
| Corcept Therapeutics | $171.92 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $160.00 | 2021-2022 | |
| Clarus Therapeutics INC. | $107.66 | 2021 | |
| Insulet Corporation | $95.03 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.17 | 2020-2022 | |
| Radius Health, INC. | $70.73 | 2019-2020 | |
| Zealand Pharma US, INC. | $54.45 | 2022 | |
| Shire North American Group INC | $45.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.72 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $40.09 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $37.34 | 2021-2022 | |
| Abbott Laboratories | $34.99 | 2020-2021 | |
| Acerus Pharmaceuticals Corporation | $33.55 | 2020 | |
| Dexcom, INC. | $32.24 | 2021-2022 | |
| Antares Pharma, INC. | $24.27 | 2019 | |
| Amryt Pharma Holdings LTD | $19.62 | 2022 | |
| Gilead Sciences, INC. | $19.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.14 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.25 | 2021 | |
| Allergan, INC. | $16.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.83 | 2019 | |
| Esperion Therapeutics, INC. | $15.03 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.95 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.60 | 2020 | |
| Merck Sharp & Dohme LLC | $12.42 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fehrenkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.